OBJECTIVES: Brentuximab vedotin is an orphan drug currently indicated for treatment of patients with refractory/relapsed hodgkin lymphoma CD30+ following prior Auto Stem Cell Transplant (ASCT) or following two prior chemotherapy regimens. This is a group of patients with a reported median survival of 12 months, with no defined standard of care and for whom clinical trials are single armed due to lack of appropriate comparators and scarcity of patients. Hence, an indirect comparison was performed to determine the cost-effectiveness of brentuximab vedotin in different countries. METHODS: A three state Markov model was developed. Effectiveness of brentuximab vedotin was obtained from the clinical trial of Gopal 2012. Effectiveness for the control group was obtained from 3 clinical trials evaluating survival of post-ASCT patients where data was disaggregated based on the patients´ response to prior ASCT/chemotherapy. The assumption was that only patients with ASCT/chemotherapy failure would serve as controls. The treatments received by the control group were based on the review of Martinez 2013, where 64% received chemotherapy, 29% AlloSCT and 8% AutoSCT. Simulations were run for the Mexican and Venezuelan contexts. Direct medical costs were obtained from the local public sectors and WHO-CHOICE. RESULTS: For the base case scenario of both countries the ICERs (USD/LYG) were respectively $38,614.34(Mex) and $57,854.07(Ven), which compares favorably against accepted ICERs in the orphan drugs field. In the univariate sensitivity analysis the model was mainly sensitive to the costs of brentuximab, AutoSCT and AlloSCT. CONCLUSIONS: Brentuximab vedotin is a cost-effective alternative for both countries, especially in the space of orphan drugs. The low costs of AutoSCT and AlloSCT in Venezuela relative to its GDP were what mainly accounted for higher ICERs. Differences in chemotherapy usage and costs did not alter the model. As a limitation, local epidemiology was not accounted for due to lack of data.